Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries

File Size53.4 KiB
DateDecember 14, 2015
AuthorJakub Zavada, William G Dixon, Johan Askling and for the EULAR Study group on Longitudinal Observational Registers and Drug Studies
The advent and increased use of targeted therapies in rheumatology have stimulated the establishment of clinical drug registers. Such registers have evaluated a broad spectrum of outcomes in patients exposed to these uniquely designed, potent and expensive drugs.1–8 Although the main focus of most drug registers in rheumatology is drug safety, other important issues include drug usage, real-life effectiveness and economic consequences.